Long-term study of FOLFIRINOX after pancreatic cancer surgery
Part of Cancer clinical trials.
This study follows people with pancreatic cancer who are receiving a chemotherapy combination called FOLFIRINOX after surgery. The goal is to see how well the treatment works over time and how it affects long-term survival and cancer recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- You are planning to receive FOLFIRINOX chemotherapy after surgery to help prevent your pancreatic cancer from returning.
- You are able to do your daily activities with little or no help (ECOG score 0 or 1).
- Your surgery removed all visible cancer (referred to as R0 or R1 resection).
- Your organs are healthy enough to handle chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares giving chemotherapy with FOLFIRINOX before and after surgery versus giving it mainly after surgery for people with resectable pancreatic duct cancer. It aims to improve outcomes by timing the treatment around the operation.
This trial tests giving mFOLFIRINOX chemotherapy after curative surgery for people with high-risk stage III colon cancer. It aims to lower the chance that cancer comes back.
This study tests a new drug (KN510713) combined with the standard chemotherapy mFOLFIRINOX for people with advanced pancreatic cancer that hasn't had prior chemotherapy. The goal is to see if adding the new drug can improve outcomes.
This Phase 2 study tests whether FOLFIRINOX given after pancreatic surgery can lower the chance the cancer comes back. It focuses on people with pancreatic ductal adenocarcinoma who had their tumor completely removed and have no spread to distant organs.
This trial tests a stronger version of FOLFIRINOX chemotherapy for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. It aims to see if the new dosing schedule works better and is safe.
This Phase 2 study looks at different types (subtypes) of pancreatic tumors in people treated with FOLFIRINOX, a chemotherapy. It requires tumor biopsies before and after treatment to see how the tumor changes, which may help doctors better match treatments in the future.
Hear when a new Adjuvant Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.